-Dow Jones
ARS Pharmaceuticals Announces Presentation Of Clinical Data Supporting neffy For the Treatment Of Allergic Reactions Type I Including Anaphylaxis
Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Supports neffy's potential to be a safe and effective option